Oct
2026
Fiera Milano, Italy
Visit us
stand 16H25, Finished Dosage & Formulation
Zone

Gan & Lee Pharmaceuticals

Exhibitor at CPHI Milan 2026
About Us

Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. 


Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions.Gan & Lee is ...

Read more Show less
Products
Show more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2021
View company profile
Contact info
  • 0086 131 2021 2399
  • No.8 Nanfeng West 1st Street, Huoxian, Tongzhou district, 101109, Beijijng, China
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 16H25, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • Basalin®(insulin glargine injection)

    Product Basalin®(insulin glargine injection)

    Basalin® is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin® is able to stablely control human blood sugar within 24...
  • GanleeFine®(pen injeciton needle)

    Product GanleeFine®(pen injeciton needle)

    GanleeFine™ is pen needle for single use, collaborately used with insulin pen or prefilled pen for insulin injection. GanleeFine™ has 5 specifications including 0.30x6mm/30G, 0.30x8mm/30G, 0.25x6mm/31G, 0.25x8mm/31G and 0.23x4mm/32G, which can meet different people's injection needs.
  • GanleePen™(reusable insulin pen)

    Product GanleePen™(reusable insulin pen)

    GanleePen is a reusable insulin pen produced by Gan & Lee's wholly-owned subsidiary, Gangan Medical Technology Co., Ltd. It has user-friendly design, big dose window, precise dose and clear reminder for dose adjustment. In addition, GanleePen is made of high-quality and reusable materials. The color of...
  • Prandilin®

    Product Prandilin®

    Prandilin® is an insulin lispro injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2007. As a fast-acting biosimilar insulin, Prandilin® is able to rapidly control human blood sugar 15-20mins after injection before a meal for the treatment of d...
  • Prandilin®25

    Product Prandilin®25

    Prandilin®25 is a premix insulin lispro suspension developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2014. As a fast-acting biosimilar insulin, Prandilin®25 is able to rapidly and stablely control human blood sugar 15-20mins after injection before a mea...

Gan & Lee Resources (1)

  • In-Depth CPHI Interview with Gan & Lee: Advancing Pharmaceutical Solutions

    Video In-Depth CPHI Interview with Gan & Lee: Advancing Pharmaceutical Solutions

    Gai Liu, Director at Gan & Lee Pharmaceuticals, shares the company’s remarkable journey, highlighting key milestones, their diverse product portfolio, and ongoing research initiatives. The interview also provides insights into Gan & Lee's international expansion strategies, talent development, and innovative approaches to staying competitive in the global pharmaceutical landscape.
    2024-11-26